vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Envela Corp (ELA). Click either name above to swap in a different company.
Envela Corp is the larger business by last-quarter revenue ($80.5M vs $44.9M, roughly 1.8× AbCellera Biologics Inc.). Envela Corp runs the higher net margin — 7.4% vs -19.9%, a 27.4% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 66.6%). Envela Corp produced more free cash flow last quarter ($-3.7M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 42.1%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Envela Corporation is a U.S.-based company that provides recommerce services aimed at extending product lifecycles and reducing resource consumption. The company operates through two primary segments: consumer and commercial.
ABCL vs ELA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $80.5M |
| Net Profit | $-8.9M | $6.0M |
| Gross Margin | — | 20.5% |
| Operating Margin | -63.7% | 9.4% |
| Net Margin | -19.9% | 7.4% |
| Revenue YoY | 788.4% | 66.6% |
| Net Profit YoY | 73.9% | 274.6% |
| EPS (diluted) | $-0.03 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $80.5M | ||
| Q3 25 | $9.0M | $57.4M | ||
| Q2 25 | $17.1M | $54.9M | ||
| Q1 25 | $4.2M | $48.3M | ||
| Q4 24 | $5.0M | $48.3M | ||
| Q3 24 | $6.5M | $46.9M | ||
| Q2 24 | $7.3M | $45.3M | ||
| Q1 24 | $10.0M | $39.9M |
| Q4 25 | $-8.9M | $6.0M | ||
| Q3 25 | $-57.1M | $3.4M | ||
| Q2 25 | $-34.7M | $2.8M | ||
| Q1 25 | $-45.6M | $2.5M | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | $-51.1M | $1.7M | ||
| Q2 24 | $-36.9M | $1.6M | ||
| Q1 24 | $-40.6M | $1.9M |
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 22.8% | ||
| Q2 25 | — | 22.6% | ||
| Q1 25 | — | 24.8% | ||
| Q4 24 | — | 23.1% | ||
| Q3 24 | — | 24.4% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 25.9% |
| Q4 25 | -63.7% | 9.4% | ||
| Q3 25 | -851.8% | 7.3% | ||
| Q2 25 | -290.2% | 5.9% | ||
| Q1 25 | -1479.6% | 6.5% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | -1439.4% | 4.3% | ||
| Q2 24 | -1276.2% | 4.2% | ||
| Q1 24 | -551.5% | 5.9% |
| Q4 25 | -19.9% | 7.4% | ||
| Q3 25 | -637.8% | 5.8% | ||
| Q2 25 | -203.3% | 5.0% | ||
| Q1 25 | -1077.2% | 5.2% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -785.4% | 3.6% | ||
| Q2 24 | -504.3% | 3.5% | ||
| Q1 24 | -408.0% | 4.8% |
| Q4 25 | $-0.03 | $0.22 | ||
| Q3 25 | $-0.19 | $0.13 | ||
| Q2 25 | $-0.12 | $0.11 | ||
| Q1 25 | $-0.15 | $0.10 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-0.17 | $0.06 | ||
| Q2 24 | $-0.13 | $0.06 | ||
| Q1 24 | $-0.14 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | $9.9M |
| Stockholders' EquityBook value | $966.9M | $67.1M |
| Total Assets | $1.4B | $96.0M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — | ||
| Q1 24 | $123.6M | $19.8M |
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.2M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | — | $13.8M | ||
| Q2 24 | — | $14.3M | ||
| Q1 24 | — | $14.6M |
| Q4 25 | $966.9M | $67.1M | ||
| Q3 25 | $964.0M | $61.1M | ||
| Q2 25 | $1.0B | $57.8M | ||
| Q1 25 | $1.0B | $55.1M | ||
| Q4 24 | $1.1B | $52.7M | ||
| Q3 24 | $1.1B | $51.1M | ||
| Q2 24 | $1.1B | $50.2M | ||
| Q1 24 | $1.1B | $49.3M |
| Q4 25 | $1.4B | $96.0M | ||
| Q3 25 | $1.4B | $90.9M | ||
| Q2 25 | $1.4B | $82.7M | ||
| Q1 25 | $1.3B | $79.7M | ||
| Q4 24 | $1.4B | $77.9M | ||
| Q3 24 | $1.4B | $77.4M | ||
| Q2 24 | $1.4B | $73.8M | ||
| Q1 24 | $1.5B | $74.7M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.29× | ||
| Q1 24 | — | 0.30× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $-3.5M |
| Free Cash FlowOCF − Capex | $-44.6M | $-3.7M |
| FCF MarginFCF / Revenue | -99.4% | -4.6% |
| Capex IntensityCapex / Revenue | 21.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $1.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $-3.5M | ||
| Q3 25 | $-52.6M | $2.4M | ||
| Q2 25 | $-32.4M | $2.6M | ||
| Q1 25 | $-11.6M | $1.1M | ||
| Q4 24 | $-108.6M | $3.7M | ||
| Q3 24 | $-28.9M | $3.4M | ||
| Q2 24 | $-30.0M | $-789.5K | ||
| Q1 24 | $-41.7M | $3.8M |
| Q4 25 | $-44.6M | $-3.7M | ||
| Q3 25 | $-61.5M | $2.2M | ||
| Q2 25 | $-45.8M | $2.1M | ||
| Q1 25 | $-22.2M | $746.6K | ||
| Q4 24 | $-187.0M | $3.2M | ||
| Q3 24 | $-47.4M | $1.5M | ||
| Q2 24 | $-50.1M | $-1.3M | ||
| Q1 24 | $-65.8M | $3.3M |
| Q4 25 | -99.4% | -4.6% | ||
| Q3 25 | -687.0% | 3.8% | ||
| Q2 25 | -267.9% | 3.9% | ||
| Q1 25 | -524.0% | 1.5% | ||
| Q4 24 | -3702.8% | 6.7% | ||
| Q3 24 | -728.4% | 3.1% | ||
| Q2 24 | -683.8% | -2.9% | ||
| Q1 24 | -661.5% | 8.4% |
| Q4 25 | 21.9% | 0.2% | ||
| Q3 25 | 99.7% | 0.4% | ||
| Q2 25 | 78.2% | 0.8% | ||
| Q1 25 | 251.1% | 0.8% | ||
| Q4 24 | 1552.7% | 1.0% | ||
| Q3 24 | 284.6% | 4.2% | ||
| Q2 24 | 274.6% | 1.1% | ||
| Q1 24 | 242.5% | 1.1% |
| Q4 25 | — | -0.59× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 2.34× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | -0.50× | ||
| Q1 24 | — | 1.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
